The Expression of EGFR Family Ligands in Breast Carcinomas
Overview
Pathology
Affiliations
Expression of EGF, HB-EGF, TGF-alpha, HRG-alpha, HRG-beta1, and HRG-beta3 in 100 frozen breast carcinoma materials was immunohistochemically studied. Among these tumors, 67% were positive for EGF, 53% for HB-EGF, 57% for TGF-alpha, 60% for HRG-alpha, 53% for HRG-beta1, and 63% for HRG-beta3 in the neoplastic epithelial cells. No significant associations between expression of the growth factors and clinicopathological features like tumor size, histologic grade, node status, ploidy, ER status, and c-erbB-4 expression were observed, with the exceptions that significant relations were present between EGF expression and tumor size (p = 0.01) and between HRG-beta3 expression and node status (p = 0.02). The expressions of these growth factors showed no association with cancer-specific survival by the Kaplan Meier analysis.
The Role of Membrane-Type 1 Matrix Metalloproteinase-Substrate Interactions in Pathogenesis.
Lee H, Ibrahimi L, Azar D, Han K Int J Mol Sci. 2023; 24(3).
PMID: 36768503 PMC: 9917210. DOI: 10.3390/ijms24032183.
Zhai J, Hsu C, Daye Z BMC Med Res Methodol. 2017; 17(1):12.
PMID: 28122498 PMC: 5267467. DOI: 10.1186/s12874-017-0291-y.
Weitzenfeld P, Meshel T, Ben-Baruch A Oncotarget. 2016; 7(49):81123-81143.
PMID: 27835603 PMC: 5348381. DOI: 10.18632/oncotarget.13213.
Lopez-Haber C, Barrio-Real L, Casado-Medrano V, Kazanietz M Mol Cell Biol. 2016; 36(15):2011-26.
PMID: 27185877 PMC: 4946436. DOI: 10.1128/MCB.00180-16.
Weitzenfeld P, Meron N, Leibovich-Rivkin T, Meshel T, Ben-Baruch A Mediators Inflamm. 2013; 2013:720536.
PMID: 24369447 PMC: 3867893. DOI: 10.1155/2013/720536.